Company news
PolyPid Ltd. news in 2023
PolyPid Ltd.'s news releases, calls and decks from 2023, newest first.
PolyPid Provides Corporate Update and Reports Third Quarter 2023 Financial Results
November 7, 2023
PolyPid Announces the Addition of Dr. Nurit Tweezer-Zaks to its Board of Directors
November 6, 2023
PolyPid to Report Third Quarter 2023 Financial Results and Operational Highlights on November 8, 2023
October 31, 2023
PolyPid Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
October 10, 2023
PolyPid Announces Presentation at the American College of Surgeons Clinical Congress 2023
October 8, 2023
PolyPid Announces Publication of Preclinical Data Further Supporting the Good Safety Profile of D-PLEX₁₀₀ and PLEX Technology Platform
October 3, 2023
PolyPid to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference
September 21, 2023
PolyPid Announces Successful Commercial Good Manufacturing Practice (GMP) Audit by Israeli Ministry of Health
September 20, 2023
PolyPid Announces Reverse Share Split
September 19, 2023
PolyPid Announces Successful Completion of Manufacturing Process Validation for D-PLEX₁₀₀
September 18, 2023
PolyPid Provides Corporate Update and Reports Second Quarter 2023 Financial Results
August 8, 2023
PolyPid to Report Second Quarter 2023 Financial Results and Operational Highlights on August 9, 2023
July 25, 2023
PolyPid Announces New Publication Highlighting Potent Antibacterial Activity of D-PLEX₁₀₀ against Susceptible and Resistant Bacteria for the Prevention of Surgical Site Infections
June 28, 2023
PolyPid Announces Recruitment of First Patient in Revised SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
June 21, 2023
PolyPid Announces 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Requirement and Transfer of its Listing to the Nasdaq Capital Market
June 4, 2023
PolyPid Announces FDA Agreement on the Design of SHIELD II Phase 3 Trial Evaluating D-PLEX₁₀₀ for Prevention of Abdominal Colorectal Surgical Site Infections
May 21, 2023
PolyPid Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 9, 2023
PolyPid to Report First Quarter 2023 Financial Results and Operational Highlights on May 10, 2023
April 25, 2023
PolyPid to Participate in Upcoming Investor Conferences
April 23, 2023
PolyPid Announces Closing of Underwritten Public Offering, Including Full Exercise of Overallotment Option, and Concurrent Private Placement with $11.4 Million in Aggregate Gross Proceeds
March 30, 2023
PolyPid Announces Pricing of $6.2 Million Underwritten Public Offering of Ordinary Shares and Concurrent $4.4 Million Private Placement of Pre-Funded Warrants
March 28, 2023
PolyPid Announces Proposed Underwritten Public Offering of Ordinary Shares
March 27, 2023
PolyPid to Present at the Barclays Global Healthcare Conference
March 6, 2023
PolyPid Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
February 7, 2023
PolyPid to Report Fourth Quarter and Full Year 2022 Financial Results and Operational Highlights on February 8, 2023
January 30, 2023
PolyPid Provides Positive Regulatory Update for D-PLEX₁₀₀ for the Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
January 23, 2023
PolyPid Announces Publication in the American Journal of Surgery of Phase 2 Clinical Trial Post-hoc Analysis for D-PLEX₁₀₀ in the Prevention of Surgical Site Infections in Abdominal Surgery
January 2, 2023